Skip to main content
Fig. 2 | Genome Medicine

Fig. 2

From: PanDrugs: a novel method to prioritize anticancer drug treatments according to individual genomic data

Fig. 2

Possible scenarios for PanDrugs therapeutic candidates. PanDrugs proposes three potential types of druggable candidates. This includes: (1) direct targets, a gene that contributes to a disease phenotype and can be directly targeted by a drug; (2) drug-resistance biomarkers, a gene which genetic status is associated with a drug response from clinical or pre-clinical evidence but its protein product is not the direct target of the drug; and (3) pathway members, a targetable gene located downstream to the altered one. To illustrate this, tumors mutated in EGFR carrying MET amplifications will not respond to EGFR inhibitors (red). PanDrugs proposes as therapeutic strategy MET inhibitors and targeting MET downstream proteins (green) to drive tumor cell death

Back to article page